Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

• Market Cap: ₹31.20B
• Dividend Yield: 0.03%
• Average Volume (3M): 2.36K
• Price to Earnings (P/E): 54.8
• Beta (1Y): 0.92
• Revenue Growth: 7.78%
• EPS Growth: -34.68%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.68
• Shares Outstanding: 100,282,510
• 10 Day Avg. Volume: 2,111
• 30 Day Avg. Volume: 2,356
• PEG Ratio: -2.39
• Price to Book (P/B): 5.63
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 124.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹316.00 ▼(-6.55% Downside)

Gufic Biosciences' overall stock score is primarily influenced by its strong financial performance, despite challenges in cash flow and debt management. Technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

Gufic shows a sustained top-line expansion (RevenueGrowth ~7.78% and cited revenue increase 2020–2025), indicating durable demand across domestic and export markets. Consistent revenue growth supports capacity utilization, reinvestment in injectables, and long-term market share gains.

Margin Sustainability

Reported solid gross and EBIT margins reflect effective cost control and manufacturing efficiency in complex dosage forms like injectables. Durable margin structure improves resilience to input cost swings and enables consistent operating cash generation when revenue scales.

Equity Position

A rising shareholders' equity and a healthy equity ratio provide a capital buffer for expansion and regulatory compliance investments. This strengthens financial stability, supports long-term manufacturing capacity buildout, and reduces insolvency risk during cyclical headwinds.

Negative Factors

Elevated Leverage

A moderately high debt-to-equity ratio increases fixed financing costs and reduces balance sheet flexibility. Over a multi-month horizon, elevated leverage can constrain funding for capex or strategic initiatives, and raises refinancing and interest-rate sensitivity risks.

Cash Flow Volatility

Irregular free cash flow and variable operating cash conversion limit the company's ability to self-fund growth, capex for injectables, and working capital needs. Persistent volatility forces reliance on external financing and weakens long-term financial predictability.

Net Income Volatility

Volatile net profit margins and intermittent net income swings reduce earnings visibility and impair the firm's ability to commit to longer-term investments or steady shareholder returns. Persistent profit variability complicates planning and increases operational risk.

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

How the Company Makes Money

Gufic Biosciences primarily generates revenue through the sale of its pharmaceutical products, which includes a wide range of generic and branded formulations. The company has established a revenue model based on both domestic and international sales, with exports contributing significantly to its earnings. Key revenue streams include sales from its injectable products, anti-infectives, and specialty medicines. Additionally, Gufic Biosciences has formed strategic partnerships and collaborations with various healthcare providers and institutions, which help enhance its market reach and drive additional revenue. The company's focus on research and development allows it to introduce new products that cater to evolving healthcare needs, further contributing to its financial growth.

Gufic Biosciences Limited Financial Statement Overview

Summary

Gufic Biosciences shows strong revenue growth and operational efficiency, but faces challenges with fluctuating net income and inconsistent cash flow. The balance sheet is stable, though the high debt-to-equity ratio requires careful management.

Income Statement

Gufic Biosciences has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2020 to 2025. The gross profit margin and EBIT margin are solid, indicating efficient cost management and operational effectiveness. However, the net profit margin has shown some fluctuations, suggesting potential volatility in net income performance.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position with a consistent increase in stockholders' equity. However, the debt-to-equity ratio is moderately high, which may pose risks if not managed carefully. The equity ratio shows a healthy proportion of equity in the capital structure, enhancing financial stability.

Cash Flow

Gufic Biosciences exhibits inconsistent free cash flow performance, with notable fluctuations in free cash flow growth rates. The operating cash flow to net income ratio shows variability, suggesting challenges in converting income into cash flow. Despite periods of negative free cash flow, recent improvements indicate potential for recovery.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.41B	8.20B	8.07B	6.91B	7.79B	4.88B
Gross Profit	4.17B	2.97B	4.07B	3.51B	3.56B	2.31B
EBITDA	1.36B	1.38B	1.48B	1.37B	1.48B	857.85M
Net Income	618.64M	696.50M	861.36M	797.05M	958.40M	442.32M
Balance Sheet
Total Assets	0.00	11.69B	10.93B	8.61B	5.21B	3.92B
Cash, Cash Equivalents and Short-Term Investments	290.22M	290.22M	11.37M	286.02M	116.08M	62.01M
Total Debt	0.00	3.36B	3.33B	3.34B	643.87M	615.37M
Total Liabilities	-6.01B	5.68B	5.60B	5.13B	2.52B	2.19B
Stockholders Equity	6.01B	6.01B	5.33B	3.48B	2.69B	1.73B
Cash Flow
Free Cash Flow	0.00	270.96M	-1.20B	-2.14B	187.86M	748.51M
Operating Cash Flow	0.00	1.03B	-74.57M	-265.87M	1.06B	872.51M
Investing Cash Flow	0.00	-717.09M	-1.02B	-1.91B	-945.89M	-66.93M
Financing Cash Flow	0.00	-163.26M	823.81M	2.34B	-62.44M	-786.18M

Gufic Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 338.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 338.15 is above the 20-day moving average (MA) of 310.69, above the 50-day MA of 331.65, and below the 200-day MA of 354.04, indicating a bearish trend. The MACD of -7.22 indicates Negative momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 53.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORCHPHARMA	64 Neutral	₹35.57B	66.81	―	―	-9.23%	-56.08%
IOLCP	60 Neutral	₹22.70B	19.60	―	0.97%	5.74%	16.06%
HIKAL	58 Neutral	₹24.19B	239.53	―	0.58%	-6.72%	-86.26%
GUFICBIO	57 Neutral	₹31.20B	54.82	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹21.48B	21.78	―	0.49%	-0.29%	-29.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹20.79B	-18.19	―	0.08%	-2.81%	-444.69%

Gufic Biosciences Limited Corporate Events

Gufic Biosciences to Appeal GST Penalty Order, Sees No Material Impact

Gufic Biosciences Limited has disclosed that it received an order from the Office of the Superintendent CGST, Ghaziabad, imposing penalties totaling about Rs 15.64 lakh for alleged excess input tax credit claims and short payment of GST for financial years 2018-19 to 2022-23. The company plans to appeal the order and, based on its assessment and legal advice, does not expect any material impact on its financial operations or other activities, suggesting limited immediate implications for shareholders and business continuity.

Gufic Biosciences Releases Earnings Call Audio

Gufic Biosciences Limited announced that the audio recording of its recent earnings conference call, held on November 17, 2025, has been uploaded to the company’s website. This move ensures transparency and provides stakeholders with easy access to the company’s financial discussions, potentially impacting investor confidence and market perception.

Gufic Biosciences Schedules Analyst and Investor Meeting

Gufic Biosciences Limited has announced a scheduled meeting with analysts and institutional investors on November 21, 2025, at the JM Financial India Xchange in Mumbai. The meeting aims to discuss already published information, ensuring no unpublished price-sensitive information is shared, reflecting the company’s commitment to transparency and regulatory compliance.